ATE335737T1 - Isoxazole und ihre verwendung als erk-inhibitoren - Google Patents

Isoxazole und ihre verwendung als erk-inhibitoren

Info

Publication number: ATE335737T1
Authority: AT; Austria
Prior art keywords: sup; isoxazoles; erk inhibitors; compounds; useful
Prior art date: 2000-09-15

Application number

AT01971002T

Other languages

English (en)

Inventor

Michael Hale

James Janetka

Francois Maltais

Jingrong Cao

Robert Mashal

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2001-09-14

Publication date

2006-09-15

2001-09-14 Application filed by Vertex Pharma filed Critical Vertex Pharma

2006-09-15 Application granted granted Critical

2006-09-15 Publication of ATE335737T1 publication Critical patent/ATE335737T1/de

Links

239000012824 ERK inhibitor Substances 0.000 title 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229940043355 kinase inhibitor Drugs 0.000 abstract 1
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
239000003909 protein kinase inhibitor Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)

AT01971002T 2000-09-15 2001-09-14 Isoxazole und ihre verwendung als erk-inhibitoren ATE335737T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US23295600P	2000-09-15	2000-09-15

Publications (1)

Publication Number	Publication Date
ATE335737T1 true ATE335737T1 (de)	2006-09-15

Family

ID=22875248

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01971002T ATE335737T1 (de)	2000-09-15	2001-09-14	Isoxazole und ihre verwendung als erk-inhibitoren

Country Status (16)

Country	Link
US (3)	US6495582B1 (de)
EP (1)	EP1317453B1 (de)
JP (1)	JP4052573B2 (de)
AT (1)	ATE335737T1 (de)
AU (1)	AU2001290940A1 (de)
CA (1)	CA2422376A1 (de)
DE (1)	DE60122176T2 (de)
ES (1)	ES2269458T3 (de)
HK (1)	HK1052934B (de)
HU (1)	HUP0302991A3 (de)
IL (1)	IL154710A0 (de)
MX (1)	MXPA03002296A (de)
NO (1)	NO325089B1 (de)
NZ (1)	NZ525016A (de)
WO (1)	WO2002022610A1 (de)
ZA (1)	ZA200301696B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1102755B1 (de) *	1998-08-07	2006-01-04	Chiron Corporation	Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US20020142982A1 (en) *	1999-09-02	2002-10-03	Timothy Hla	Method for regulating angiogenesis
US7074794B2 (en) *	2000-08-10	2006-07-11	Mitsubishi Pharma Corporation	Proline derivatives and the use thereof as drugs
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (de)	2000-09-15	2006-11-22	Vertex Pharmaceuticals Incorporated	Pyrazolverbindungen als protein-kinasehemmer
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) *	2000-12-21	2004-04-30	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors
US6589997B2 (en) *	2001-06-29	2003-07-08	North Shore-Long Island Jewish Health System	Small-molecule modulators of hepatocyte growth factor/scatter factor activities
ATE491701T1 (de) *	2001-08-03	2011-01-15	Vertex Pharma	Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EP1435948A1 (de) *	2001-08-06	2004-07-14	Pharmacia Italia S.p.A.	Aminoisoxazol-derivate mit wirkung als kinasehemmer
EP1472245A2 (de) *	2002-02-06	2004-11-03	Vertex Pharmaceuticals Incorporated	Heteroaryl-verbindungen und ihre anwendung als gsk-3-hemmer
AU2003218215A1 (en) *	2002-03-15	2003-09-29	Vertex Pharmaceuticals, Inc.	Azolylaminoazines as inhibitors of protein kinases
MY141867A (en) *	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
US7015227B2 (en)	2002-06-21	2006-03-21	Cgi Pharmaceuticals, Inc.	Certain amino-substituted monocycles as kinase modulators
DK1532145T3 (da)	2002-08-02	2007-01-15	Vertex Pharma	Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
PT1537116E (pt)	2002-09-04	2010-09-03	Schering Corp	Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004022561A1 (en)	2002-09-04	2004-03-18	Schering Corporation	Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7605155B2 (en)	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8673924B2 (en)	2002-09-04	2014-03-18	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en)	2002-09-04	2006-10-10	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en)	2002-09-04	2013-11-12	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
WO2004072029A2 (en) *	2003-02-06	2004-08-26	Vertex Pharmaceuticals Incorporated	Pyrazolopyridazines useful as inhibitors of protein kinases
CA2536470A1 (en)	2003-08-15	2005-02-24	Vertex Pharmaceuticals Incorporated	Pyrrole compositions useful as inhibitors of c-met
AU2004297235A1 (en) *	2003-12-04	2005-06-23	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
US8513437B2 (en) *	2004-07-26	2013-08-20	Ben Gurion University Of The Negev Research And Development Authority	Pyrrolidino-1,4-naphthoquinone deriviatives and their use for treating malignancies and cardiovascular diseases
US7429667B2 (en) *	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
NZ560712A (en)	2005-02-17	2010-12-24	Synta Pharmaceuticals Corp	(3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
AU2006279376B2 (en) *	2005-08-18	2011-04-14	Vertex Pharmaceuticals Incoporated	Pyrazine kinase inhibitors
CN101263139A (zh) *	2005-09-19	2008-09-10	弗·哈夫曼-拉罗切有限公司	作为GABA Aα5逆激动剂的异唑衍生物
CN101321760A (zh)	2005-10-06	2008-12-10	先灵公司	作为蛋白激酶抑制剂的吡唑并嘧啶
CN101316847A (zh)	2005-10-06	2008-12-03	先灵公司	用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
EP1954277B1 (de) *	2005-11-03	2017-01-18	Vertex Pharmaceuticals Incorporated	Als kinaseinhibitoren geeignete aminopyrimidine
TW200804386A (en)	2005-11-10	2008-01-16	Schering Corp	Imidazopyrazines as protein kinase inhibitors
US8546404B2 (en)	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
KR101394245B1 (ko) *	2005-12-30	2014-05-14	에스케이바이오팜 주식회사	아이속사졸 유도체 및 이의 용도
MX2008010635A (es)	2006-02-16	2008-10-28	Schering Corp	Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
US7842836B2 (en)	2006-04-11	2010-11-30	Ardea Biosciences	N-aryl-N'alkyl sulfamides as MEK inhibitors
MX2008013097A (es) *	2006-04-18	2008-10-27	Ardea Biosciences Inc	Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
US20090175852A1 (en)	2006-06-06	2009-07-09	Schering Corporation	Imidazopyrazines as protein kinase inhibitors
AR063531A1 (es)	2006-10-31	2009-01-28	Schering Corp	Derivados de anilinopiperazina y composicion farmaceutica
CA2668210C (en)	2006-10-31	2013-03-12	Schering Corporation	Anilinopiperazine derivatives and methods of use thereof
MX2009004785A (es)	2006-10-31	2009-06-05	Schering Corp	Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
MX2009004807A (es) *	2006-11-02	2009-06-15	Vertex Pharma	Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
NZ577768A (en) *	2006-12-19	2012-01-12	Vertex Pharma	Aminopyrimidines useful as inhibitors of protein kinases
MX2009009590A (es) *	2007-03-09	2009-11-10	Vertex Pharma	Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009009592A (es) *	2007-03-09	2009-11-10	Vertex Pharma	Aminopiridinas utiles como inhibidores de proteinas cinasas.
ATE526328T1 (de) *	2007-03-09	2011-10-15	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
AU2008240313A1 (en)	2007-04-13	2008-10-23	Aj Park	Aminopyrimidines useful as kinase inhibitors
US8509487B2 (en) *	2007-04-19	2013-08-13	Avago Technologies General Ip (Singapore) Pte. Ltd.	System and method for optically measuring a parameter of an object
JP5389786B2 (ja) *	2007-05-02	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼ阻害として有用なアミノピリミジン
CN101679387A (zh) *	2007-05-02	2010-03-24	沃泰克斯药物股份有限公司	可用作激酶抑制剂的氨基嘧啶类化合物
AU2008247592A1 (en)	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
MX2009012719A (es) *	2007-05-24	2010-02-04	Vertex Pharma	Tiazoles y pirazoles utiles como inhibidores de cinasa.
JP5241834B2 (ja)	2007-07-19	2013-07-17	メルク・シャープ・アンド・ドーム・コーポレーション	プロテインキナーゼ阻害剤としての複素環アミド化合物
CN101790532B (zh) *	2007-07-31	2013-11-20	沃泰克斯药物股份有限公司	5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
AU2008293542B9 (en)	2007-08-27	2014-08-07	Dart Neuroscience (Cayman) Ltd.	Therapeutic isoxazole compounds
CA2703978A1 (en)	2007-10-29	2009-05-07	Schering Corporation	Thiazole derivatives as protein kinase inhibitors
WO2009105500A1 (en)	2008-02-21	2009-08-27	Schering Corporation	Compounds that are erk inhibitors
EP2303258A4 (de) *	2008-06-26	2012-03-14	Glaxosmithkline Llc	Hemmer der akt-aktivität
WO2010027921A1 (en) *	2008-09-03	2010-03-11	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical formulations comprising the same
WO2011025706A2 (en)	2009-08-26	2011-03-03	Schering Corporation	Heterocyclic amide compounds as protein kinase inhibitors
EP2600862B1 (de)	2010-08-05	2016-04-20	Case Western Reserve University	Erk-hemmer für entwicklungsstörungen der neuronalen konnektivität
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
DK2841075T3 (da)	2012-04-26	2020-06-22	Massachusetts Gen Hospital	Midler og fremgangsmåder til behandling og forebyggelse af seboroisk keratose
ES2661394T3 (es)	2012-07-16	2018-03-28	Neuropore Therapies, Inc.	Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas
WO2014186663A2 (en) *	2013-05-17	2014-11-20	The General Hospital Corporation	Methods for detecting and treating variants of seborrheic keratoses
CN105764501A (zh)	2013-07-26	2016-07-13	现代化制药公司	改善比生群治疗效益的组合物
EP3046557A1 (de)	2013-09-20	2016-07-27	Stichting Het Nederlands Kanker Instituut	Rock in kombination mit mapk-signalweg
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
CA2935804A1 (en)	2014-01-14	2015-07-23	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2017058007A1 (en)	2015-10-01	2017-04-06	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
WO2017099591A1 (en)	2015-12-07	2017-06-15	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en)	2016-05-24	2017-11-30	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5498720A (en) *	1993-08-26	1996-03-12	Lee; An-Rong	Certain triazole compounds and their pharmaceutical uses
DE4438824A1 (de) *	1993-10-16	1995-04-20	Schering Ag	Triazolderivate, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln
JP3542827B2 (ja) *	1994-07-15	2004-07-14	帝国臓器製薬株式会社	新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体
US5470862A (en)	1995-02-03	1995-11-28	Ohmeda Pharmaceutical Products Division Inc.	Substituted pyrazolyl compounds and methods employing such compounds
UA52698C2 (uk)	1996-10-04	2003-01-15	Х. Луннбек А/С	Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
CA2251580A1 (en) *	1997-02-14	1998-08-20	Bayer Corporation	Amides as npy5 receptor antagonists
WO1999061440A1 (en)	1998-05-26	1999-12-02	Smithkline Beecham Corporation	Novel substituted imidazole compounds
JP4191825B2 (ja)	1998-09-10	2008-12-03	あすか製薬株式会社	５−アミノイソキサゾール誘導体
HUP0202332A2 (en)	2000-02-05	2002-10-28	Vertex Pharma	Pyrazole compositions useful as inhibitors of erk
WO2001056557A2 (en) *	2000-02-05	2001-08-09	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of erk
CA2536470A1 (en) *	2003-08-15	2005-02-24	Vertex Pharmaceuticals Incorporated	Pyrrole compositions useful as inhibitors of c-met

2001
- 2001-09-14 AT AT01971002T patent/ATE335737T1/de not_active IP Right Cessation
- 2001-09-14 ES ES01971002T patent/ES2269458T3/es not_active Expired - Lifetime
- 2001-09-14 ZA ZA200301696A patent/ZA200301696B/en unknown
- 2001-09-14 IL IL15471001A patent/IL154710A0/xx unknown
- 2001-09-14 EP EP01971002A patent/EP1317453B1/de not_active Expired - Lifetime
- 2001-09-14 DE DE60122176T patent/DE60122176T2/de not_active Expired - Lifetime
- 2001-09-14 MX MXPA03002296A patent/MXPA03002296A/es not_active Application Discontinuation
- 2001-09-14 CA CA002422376A patent/CA2422376A1/en not_active Abandoned
- 2001-09-14 HU HU0302991A patent/HUP0302991A3/hu unknown
- 2001-09-14 AU AU2001290940A patent/AU2001290940A1/en not_active Abandoned
- 2001-09-14 HK HK03105158.4A patent/HK1052934B/en not_active IP Right Cessation
- 2001-09-14 US US09/953,120 patent/US6495582B1/en not_active Expired - Lifetime
- 2001-09-14 JP JP2002526863A patent/JP4052573B2/ja not_active Expired - Fee Related
- 2001-09-14 NZ NZ525016A patent/NZ525016A/en unknown
- 2001-09-14 WO PCT/US2001/028790 patent/WO2002022610A1/en not_active Ceased
2002
- 2002-10-15 US US10/272,622 patent/US6649640B2/en not_active Expired - Fee Related
2003
- 2003-03-14 NO NO20031192A patent/NO325089B1/no not_active IP Right Cessation
- 2003-07-24 US US10/626,356 patent/US7354919B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6649640B2 (en)	2003-11-18
ZA200301696B (en)	2004-04-28
HUP0302991A3 (en)	2009-10-28
EP1317453A1 (de)	2003-06-11
US20050090536A1 (en)	2005-04-28
US6495582B1 (en)	2002-12-17
JP4052573B2 (ja)	2008-02-27
EP1317453B1 (de)	2006-08-09
US20030195241A1 (en)	2003-10-16
NO20031192D0 (no)	2003-03-14
CA2422376A1 (en)	2002-03-21
WO2002022610A1 (en)	2002-03-21
NZ525016A (en)	2004-10-29
AU2001290940A1 (en)	2002-03-26
NO20031192L (no)	2003-05-13
HK1052934B (en)	2007-01-12
ES2269458T3 (es)	2007-04-01
HK1052934A1 (en)	2003-10-03
IL154710A0 (en)	2003-10-31
DE60122176D1 (de)	2006-09-21
JP2004509119A (ja)	2004-03-25
DE60122176T2 (de)	2007-07-05
US7354919B2 (en)	2008-04-08
HUP0302991A2 (hu)	2003-12-29
NO325089B1 (no)	2008-01-28
MXPA03002296A (es)	2003-06-06
US20020177618A1 (en)	2002-11-28

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1317453

Country of ref document: EP

2010-06-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE335737T1 (de)	2006-09-15	Isoxazole und ihre verwendung als erk-inhibitoren
ATE491701T1 (de)	2011-01-15	Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
ATE392421T1 (de)	2008-05-15	Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
MXPA03009846A (es)	2004-05-05	Derivados de triazol inhibidores de cinasa y usos de los mismos.
WO2001056993A3 (en)	2002-01-10	Pyrazole compositions useful as inhibitors of erk
LT2001103A (en)	2002-10-25	Pyrazole compositions useful as inhibitors of erk
AP2003002853A0 (en)	2003-09-30	Heterocyclic inhibitors of ERK2 and uses thereof
WO2002088090A3 (en)	2004-07-22	Pyrazole derived kinase inhibitors
BG108181A (bg)	2004-09-30	Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7
EA200300248A1 (ru)	2003-08-28	Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
DE60315146D1 (de)	2007-09-06	Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE420879T1 (de)	2009-01-15	Indolizine als kinaseproteinhemmer
CY1112100T1 (el)	2015-11-04	ΝΕΑ ΕΝΩΣΗ ΤΡΙΣΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8Η-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-7-ΟΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΑΣΘΕΝΕΙΩΝ, ΟΙ ΟΠΟΙΕΣ ΕΧΟΥΝ ΠΡΟΚΛΗΘΕΙ ΜΕ ΤΗ ΜΕΣΟΛΑΒΗΣΗ CSBP/p38 ΚΙΝΑΣΗΣ
UA88012C2 (uk)	2009-09-10	Похідні хіназоліндіону як інгібітори parp
EA200200862A1 (ru)	2003-02-27	Пирролзамещенный 2-индолинон и промежуточный пиррол, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
DE60205776T2 (de)	2006-06-14	Indolinon-derivative als protein-kinasehemmer
MXPA03010961A (es)	2004-02-27	Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
DE602004024988D1 (de)	2010-02-25	2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE275544T1 (de)	2004-09-15	Serinprotease-inhibitoren
ATE287886T1 (de)	2005-02-15	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE60106409D1 (de)	2004-11-18	3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
BRPI0415390A (pt)	2006-12-12	compostos de pirazinona substituìda para o tratamento da inflamação
DE60127131D1 (de)	2007-04-19	Tricyclische imidazopyridine
EA200301101A1 (ru)	2004-04-29	Производные пиперазина и их применение в качестве ингибиторов pde4
ATE403422T1 (de)	2008-08-15	Substituierte hydrazone als hemmer von cyclooxygenase-2